BioInvent International AB (publ) (STO:BINV)
Sweden · Delayed Price · Currency is SEK 22.15
-1.10 (-4.73%)
At close: Mar 2, 2026
STO:BINV Revenue
In the year 2025, BioInvent International AB had annual revenue of 226.50M SEK with 406.86% growth. BioInvent International AB had revenue of 3.02M in the quarter ending December 31, 2025, a decrease of -85.89%.
Revenue
226.50M
Revenue Growth
+406.86%
P/S Ratio
6.75
Revenue / Employee
1.83M
Employees
109
Market Cap
1.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 226.50M | 181.81M | 406.86% |
| Dec 31, 2024 | 44.69M | -26.78M | -37.47% |
| Dec 31, 2023 | 71.46M | -254.67M | -78.09% |
| Dec 31, 2022 | 326.13M | 306.74M | 1,582.45% |
| Dec 31, 2021 | 19.38M | -127.99M | -86.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Saniona AB | 434.40M |
| Cantargia AB | 316.70M |
| Hansa Biopharma AB | 222.27M |
| Genovis AB (publ.) | 129.65M |
| Egetis Therapeutics AB | 62.40M |
| Medivir AB | 8.50M |
| Xspray Pharma AB | 6.43M |
| Vicore Pharma Holding AB | 3.82M |
BioInvent International AB News
- 4 days ago - BioInvent International AB (FRA:BIX0) Q4 2025 Earnings Call Highlights: Navigating Challenges ... - GuruFocus
- 4 days ago - BioInvent International AB (publ) 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 4 days ago - Q4 2025 BioInvent International AB Earnings Call Transcript - GuruFocus
- 4 months ago - BioInvent International AB (FRA:BIX0) Q3 2025 Earnings Call Highlights: Strategic Focus Amidst ... - GuruFocus
- 4 months ago - Q3 2025 BioInvent International AB Earnings Call Transcript - GuruFocus
- 4 months ago - BioInvent International AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 4 months ago - BioInvent International AB (publ) (BOVNF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments - Benzinga